Table 2.
Clinical outcomes.
| Outcomes | Mean ± SD | Median ± IQR | OR | 95% CI | P value | |||
|---|---|---|---|---|---|---|---|---|
| CQ-AP | The commercialized rectal suppository | CQ-AP | The commercialized rectal suppository | |||||
| Anal pain | ||||||||
| VAS (score)∗ | Day 1 | 3.63 ± 2.39 | 3.17 ± 2.49 | 4.0 ± 3.0 | 3.0 ± 4.0 | 0.36 | 0.12–1.03 | 0.057 |
| Day 4 | 1.61 ± 1.74 | 0.82 ± 1.30 | 1.0 ± 2.0 | 0.0 ± 1.3 | ||||
| Day 8 | 0.80 ± 1.22 | 0.64 ± 1.26 | 0.0 ± 1.0 | 0.0 ± 1.0 | ||||
|
| ||||||||
| Bleeding | ||||||||
| Severity (score)∗∗ | Day 1 | 1.23 ± 0.72 | 1.32 ± 0.78 | 1 ± 1 | 1 ± 1 | 1.47 | 0.34–6.32 | 0.610 |
| Day 4 | 0.21 ± 0.50 | 0.22 ± 0.64 | 0 ± 0 | 0 ± 0 | ||||
| Day 8 | 0.06 ± 0.31 | 0.16 ± 0.50 | 0 ± 0 | 0 ± 0 | ||||
|
| ||||||||
| Prolapse | Beta | 95% CI | P value | |||||
| Size (cm) | Day 1 | 1.31 ± 0.71 | 1.42 ± 0.72 | 1.0 ± 0.6 | 1.2 ± 0.9 | −0.07 | −0.23–0.10 | 0.414 |
| Day 8 | 0.76 ± 0.58 | 0.75 ± 0.53 | 0.5 ± 0.5 | 0.7 ± 0.6 | ||||
| Size reduced (cm)∗∗∗ | 0.84 ± 0.68 | 0.87 ± 0.62 | 1.0 ± 1.2 | 1.0 ± 0.5 | 0.923 | |||
∗ Pain severity measured by the visual analog scale ranging from 0 to 10, where 0 point indicates no pain at all and 10 points indicate the most severe pain. ∗∗Bleeding severity: 1 point for no bleeding, 2 points for having bleeding during some instances of defecation, 3 points for bleeding in every instance of defecation, and 4 points for large amount of bleeding during every instance of defecation. ∗∗∗Prolapse size reduction score: 0 point for insignificant size reduction, 1 point for 40–70% reduction, and 2 points for greater than 70% reduction. Data are expressed as the number (percentage) of patients or mean ± SD, unless otherwise indicated.